Genecast founder and CEO, is currently a young member of the Biomedical Technology Branch of the China Pharmaceutical Biotechnology Association.

Dubo is one of the first developers to enter the NGS field in China, and co-founded the first NGS reagent manufacturer in China, Nanjing Keweisi Biotechnology Co., Ltd.

Du Bo has been invited to attend conferences in the field of biomedical sciences and has been awarded many awards including the China Pharmaceutical Association's Technology Progress Award.

Du Bo graduated from the Department of Biology, Beijing University.

Henghui Zhang, M.D., PhD, Co-founder and Chief Medical Officer of Genecast (Beijing) Biotechnology Co. 

Henghui Zhang has been engaged in clinical and translational work for more than 10 years. This has endowed him with immense experience in clinical oncology and scientific research. He has participated in and lead a number of fund projects, including the National Natural Science Foundation of China, the Natural Science Funds of Beijing Municipality and the Doctoral Fund of Ministry of Education of China, among others. Simultaneously, he was a major participant in the national Eleventh Five-Year and Twelfth Five-Year Science and Technology Development Plans, has won four national invention patents, and has published more than 50 SCI papers. On top of this, he took the lead role of responsibility in the patent transfer of a new drug for a cancer vaccine therapy (0.12 billion RMB).

Prior to co-founding Genecast, Henghui Zhang worked at Peking University People’s Hospital and Peking University Hepatology Institute, and was engaged in clinical and translational work for more than 10 years. In roles such as project leader and co-leader, he was involved in preclinical development and research work for a number of therapeutic cancer vaccines and molecular diagnostics projects. 

Henghui Zhang graduated from Peking University with a master’s degree in medicine, and a doctorate in immunology from Capital Medical University.

Guosheng Ma has more than 20 years of experience in the marketing and management of oncology drugs. He has obtained an in-depth understanding of the domestic pharmaceutical environment as well as its industry trends, and has unique insights into oncology drug marketing. 

In 2006, Guosheng Ma built a team of professionals to lead the launch of the anti-EGFR monoclonal antibody, cetuximab, in China and, in 2009, achieved sales of nearly 500 million yuan.

In 2010, Guosheng Ma joined Baitai Bio to lead up its marketing and sales. He successfully reversed its unfavorable market situation and grew sales of Nimotuzumab, China’s first independent anti-EGFR drug, to reach 500 million yuan, surpassing the market share of the original brand-name product by a multinational company.

Guosheng Ma studied medicine at Capital Medical University, graduating in 1988, and continued working there as an instructor until 1997.

Tao Yang, deputy general manager of Genecast (Beijing) Biotechnology Co. 

Tao Yang has worked in the healthcare industry for more than a decade and has worked in marketing and management functions for well-known foreign and private pharmaceutical biotechnology companies, including Sino-Swiss joint venture Sino-Swed Pharmaceutical Co., Ltd., Sino-US joint venture Suzhou Lida Pharmaceutical Co., Ltd., Schering-Plough (China) Co., Ltd., Sino-American joint venture Shanghai Schering-Ploughs Pharmaceutical Co., Ltd., Beijing Zheng Qing Yuan Bio-Engineering Co., Ltd., and Nanjing Ai Qirui Molecular Biotechnology Co., Ltd.

Prior to this, Tao Yang worked for eight years at a clinical hospital as a physician, rising to the position of chief physician of internal medicine, and accumulating a wealth of experience in clinical medicine and medical management.

Tao Yang graduated in medicine from Nanjing Medical College.

Ji He is the chief information officer of Genecast Biotechnology Co., Ltd. He has worked in many leading international enterprises, including OmniSeq, BioReference Laboratories, Leidos and Samuel Roberts Noble Foundation, where he lead in roles such as VP of bioinformatics, bioinformatics director, bioinformatics manager and director of scientific computing.

Ji He has an enormous amount of experience working internationally. He has more than a decade of experience in bioscience, and has gained outstanding achievements in genomics, biomedicine, informatics and computing. At OmniSeq, he developed the US’s first NGS diagnostic panel for cancer immunotherapy to be approved by NYS CLEP. He has published more than 40 articles in renowned international academic periodicals, including both Nature Genetics and Blood, and been in charge of seven research projects funded, with a total value of over 15 million dollars, by the United States Federal Government or state government.